Gilead Sciences, Inc. (LON:0QYQ)

Market Cap	98.31B
Revenue (ttm)	22.97B
Net Income (ttm)	383.41M
Shares Out	n/a
EPS (ttm)	0.30
PE Ratio	256.41
Forward PE	n/a
Dividend	2.41 (2.32%)
Ex-Dividend Date	Mar 14, 2025

Volume	4,666
Average Volume	27,123
Open	101.95
Previous Close	102.07
Day's Range	100.85 - 104.69
52-Week Range	49.43 - 78.63
Beta	0.34
RSI	43.23
Earnings Date	Apr 24, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QYQ

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD